CBRE vs CME Stock Comparison
Compare CBRE and CME across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between CBRE and CME?
CME leads the current stock comparison as CME Group Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
CBRE Group, Inc. vs CME Group Inc.
CME leads
CME leads by 10 AIQ points, primarily on Quality and Momentum, and the lead has widened from 1 points over 30 sessions. Wall Street currently favors CBRE on target upside.
Competitive: 4 of 6 evidence groups support CME, and its lead is widening.
CBRE Group, Inc.
CME Group Inc.
The Algovestiq AIQ Score currently favors CME over CBRE, 52 versus 42 as of Sep 11, 2026. CME's advantage is driven primarily by stronger quality and momentum, while CBRE holds the stronger value profile. CME also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors CBRE. 4 of 6 covered evidence groups favor CME today, and the comparison is rated Competitive on stability. CME lead: Strengthening — the AIQ differential moved from 1 to 10 points over 30 sessions.
Compare CBRE Group, Inc. and CME Group Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare CBRE and CME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality34 vs 74CME +40
- Value65 vs 26CBRE +39
- Momentum20 vs 54CME +34
- Risk Resilience49 vs 56CME +7
4 of 6 evidence groups favor CME. CME’s edge is concentrated in quality and momentum; CBRE keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -1
New signals
- Keltner Channel Breakdown — bearish, volatility, short horizon
Largest factor move: Momentum -5
No new signals fired.
CME's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — CBRE and CME both carry a full feed there.
The central trade-off
CME (CME Group Inc.): the stronger current systematic profile, led by quality and momentum.
CBRE (CBRE Group, Inc.): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 39.6% against 21.7%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
CMECME on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
CMECME on combined revenue and EPS growth.
Value
CBRECBRE on the peer-relative Value factor, by 39 points.
Momentum
CMECME on the Momentum factor, by 34 points.
Lower downside
CMECME on Risk Resilience, by 7 points.
Analyst upside
CBRECBRE on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors CME, analyst targets favor CBRE. That disagreement is the most useful thing on this page.
| Measure | CBRE | CME | Note |
|---|---|---|---|
| Implied upside to target | +26% | +14.9% | CBRE has more room |
| Target dispersion | +7.9% | +32.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 2 | 6 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor CME. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | CME | 42 vs 52 |
| Fundamentals | CMEon balance | revenue growth 6.6% vs -9.2%; EPS growth -36.1% vs -12%; TTM ROE 15.2% vs 15.5%; gross margin 17.7% vs 81.9%; operating margin 3.6% vs 65.1% — CME takes 3 of 4 decided legs, not all of them |
| Valuation | CBRE | Value 65 vs 26 |
| Technicals | CME | Price vs 50-day -3.1% vs 5.3%; vs 200-day -6.1% vs -1.7% |
| Risk Resilience | CME | Risk Resilience 49 vs 56 |
| Analyst expectations | CBRE | Target upside 26% vs 14.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of CBRE and CME and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 10 points.
- The leader's advantage has been widening. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on CME.
How the comparison changed
119 daily snapshots · May 4 – Sep 10CME lead: Strengthening — the AIQ differential moved from 1 to 10 points over 30 sessions.
- Today
- CME +10
- 42 vs 52
- 7 sessions ago
- CME +5
- 52 vs 57
- 30 sessions ago
- CME +1
- 52 vs 53
- 90 sessions ago
- CBRE +9
- 54 vs 45
The lead changed hands 2 times in this window, most recently on Jul 14 when CME moved ahead of CBRE.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 4 bearish, conflicted
- Death Cross Active — bearish, trend, long horizon (1.37%)
- BB Lower Band Breach — bullish, volatility, short horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
0 bullish / 2 bearish
- Death Cross Active — bearish, trend, long horizon (6.50%)
- MACD Bearish Crossover — bearish, momentum, short horizon
CBRE is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.83%, AIQ 0 points).
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.54%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1CBRE closes the Quality gap — currently 40 points behind, the largest single contributor to CME's edge.
- 2CBRE's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3CME starts generating bearish momentum or trend signals.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
CME leads on balance| Metric | CBRE | CME |
|---|---|---|
| Revenue growth (YoY) | 6.6% | -9.2% |
| EPS growth (YoY) | -36.1% | -12% |
| Gross margin | 17.7% | 81.9% |
| Operating margin | 3.6% | 65.1% |
| Return on equity (TTM) | 15.2% | 15.5% |
| Debt to equity | 1.26 | 0.13 |
Performance
CME leads 5 of 6 windows| Metric | CBRE | CME |
|---|---|---|
| 1 week (5 sessions) | -2.9% | -1.3% |
| 1 month (20 sessions) | -6.4% | 4.5% |
| 3 months (63 sessions) | 2.9% | 3.9% |
| 6 months (126 sessions) | 4.2% | -9.6% |
| Year to date | -14.2% | 0.4% |
| 1 year (252 sessions) | -15.3% | 4.4% |
Technicals
CME has the stronger structure| Metric | CBRE | CME |
|---|---|---|
| RSI (14) | 30.3 | 53.9 |
| ADX (14) | 17.2 | 22.7 |
| Price vs 50-day | -3.1% | 5.3% |
| Price vs 200-day | -6.1% | -1.7% |
| Volatility (1M, annualized) | 39.6% | 21.7% |
Risk
CME is the more resilient| Metric | CBRE | CME |
|---|---|---|
| Beta | 0.83 | -0.32 |
| Sharpe ratio | -0.45 | 0.15 |
| Sortino ratio | -0.59 | 0.21 |
| Max drawdown | -27.4% | -33% |
| Current drawdown | -19.6% | -16.1% |
| Annualized volatility | 32.7% | 23.9% |
| Value at risk (95%) | -3.1% | -2.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, CBRE or CME?
On the Algovestiq AIQ Score, CME is the stronger of the two as of Sep 11, 2026, scoring 52 against CBRE's 42. The edge comes from quality and momentum. CBRE is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is CBRE or CME the better buy right now?
CME carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor CME over CBRE?
The composite weights Quality, Value, Momentum and Risk Resilience. CME leads Quality by 40 points; CBRE leads Value by 39 points; CME leads Momentum by 34 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, CBRE or CME?
Analyst price targets imply +26% upside for CBRE and +14.9% for CME, so the Street currently favors CBRE. That points the opposite way to the AIQ Score, which favors CME. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, CBRE or CME?
CBRE is the better-valued of the two on the peer-relative Value factor. CBRE on the peer-relative Value factor, by 39 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, CBRE or CME?
CME on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, CBRE or CME?
CME on the Momentum factor, by 34 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, CBRE or CME?
CME is the more resilient of the two, so the other name carries the higher downside risk. CME on Risk Resilience, by 7 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is CBRE more profitable than CME?
CME leads on the comparable margin measures — gross margin 17.7% vs 81.9%; operating margin 3.6% vs 65.1%; ttm roe 15.2% vs 15.5%.
Is CME's lead over CBRE getting stronger or weaker?
CME lead: Strengthening — the AIQ differential moved from 1 to 10 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 2 times in that window, most recently on 2026-07-14, when CME moved ahead of CBRE.
What would change the CBRE vs CME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: CBRE closes the Quality gap — currently 40 points behind, the largest single contributor to CME's edge; CBRE's Death Cross Active resolves — a bearish trend rule currently active against it; CME starts generating bearish momentum or trend signals; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about CBRE and CME?
CBRE: 1 bullish / 4 bearish, conflicted. CME: 0 bullish / 2 bearish. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on CBRE is Death Cross Active (bearish, long horizon). On CME it is Death Cross Active (bearish, long horizon).
Compare CBRE and CME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.